ReutersReuters

Merus’ Petosemtamab With Pembrolizumab Interim Data Demonstrates Robust Efficacy And Durability In 1L Pd-L1+ R/M Hnscc

Refinitiv1분 미만 읽기

Merus NV MRUS:

  • MERUS’ PETOSEMTAMAB WITH PEMBROLIZUMAB INTERIM DATA DEMONSTRATES ROBUST EFFICACY AND DURABILITY IN 1L PD-L1+ R/M HNSCC

이 뉴스를 읽으려면 로그인하거나 평생 무료 계정을 만드십시오